V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 330004389 | 330002141 | null | 57.5 | Palliative (P) | 2014-06-04 | 2014-06-13 | VIDE | N | N | 330017649 | DOXORUBICIN + IFOSFAMIDE |
| 330004390 | 330002141 | 1.68 | 0 | Palliative (P) | 2018-10-13 | 2018-10-13 | Cyclophosphamide High Dose | N | Y | 330017649 | GDP |
| 330004391 | 330002142 | 1.77 | null | Disease modification (D) | 2014-07-16 | 2014-07-24 | Imatinib 600mg | 2 | N | 330017664 | CETUXIMAB + CISPLATIN + FLUOROURACIL |
| 330004392 | 330002143 | 1.81 | null | Curative (C) | 2017-09-25 | 2017-09-25 | BCG Intravesical | Y | N | 330017665 | BENDAMUSTINE |
| 330004393 | 330007180 | 1.53 | 76 | Palliative (P) | 2014-05-14 | 2014-05-17 | CISPLATIN + DOX + ETOPOSIDE + MITOTANE | N | N | 330017668 | CARBOPLATIN + RT |
| 330004394 | 330009892 | 0 | 59.7 | Curative (C) | 2015-06-18 | 2015-06-18 | CISPLATIN + VINORELBINE | 2 | N | 330017672 | FCR |
| 330004400 | 330002144 | 1.73 | 73.5 | Palliative (P) | 2014-09-04 | 2014-09-04 | Cisplatin + Fluorouracil + RT 5day | 02 | N | 330017716 | ABVD |
| 330004401 | 330002144 | 1.62 | 78 | Palliative (P) | 2015-04-11 | 2015-04-12 | ETOPOSIDE | N | null | 330017716 | FLAG + IDARUBICIN |
| 330004402 | 330002145 | 1.58 | 58 | Palliative (P) | 2015-02-22 | 2015-02-25 | Doxorubicin + Ifosfamide | 02 | N | 330017729 | ALL INTERIM GUIDELINES |
| 330004403 | 330007182 | null | 79.5 | Not known (9) | 2015-01-23 | 2015-02-22 | VIDE | 2 | null | 330017738 | ATG + BUSULFAN + FLUDARABINE |
| 330004404 | 330007182 | 1.6 | 93.8 | Curative (C) | 2013-04-16 | 2013-04-29 | Cytarabine Low Dose | N | N | 330017738 | CISPLATIN + PEMETREXED |
| 330004405 | 330011402 | 1.77 | 82 | Curative (C) | 2017-08-22 | 2017-08-24 | Cyclophosphamide oral | null | N | 330017741 | CAPECITABINE + CARBOPLATIN |
| 330004407 | 330002147 | 1.75 | 70.3 | Palliative (P) | 2013-08-09 | 2013-08-21 | Doxorubicin + Olaratumab | N | N | 330017751 | VINCRISTINE |
| 330004408 | 330002147 | 1.7 | 76.9 | Palliative (P) | 2014-04-27 | 2014-04-27 | Cisplatin + Fluorouracil + RT 5day | 02 | N | 330017751 | HYDROXYCARBAMIDE |
| 330004409 | 330002148 | 0 | 74.65 | Curative (C) | 2017-08-01 | 2017-08-14 | Docetaxel+Gemcitabine (no prior RT) | N | N | 330017763 | UKALL 2011 |
| 330004410 | 330007184 | 1.52 | 65.3 | Curative (C) | 2014-07-01 | 2014-09-21 | Alemtuz+Fludara+Melphalan RIC MUD | N | N | 330017778 | CVD |
| 330004411 | 330002149 | 1.74 | 89.7 | Palliative (P) | 2014-04-02 | 2014-04-02 | CYTARABINE | N | N | 330017780 | FCR |
| 330004412 | 330002149 | 0 | 80.1 | Adjuvant (A) | null | 2017-05-20 | CARBOPLATIN + RT | N | N | 330017780 | UKALL 2011 |
| 330004413 | 330002149 | 1.77 | 58.4 | Curative (C) | 2014-12-27 | 2015-01-01 | Cisplatin + Fluorouracil + RT 5day | N | N | 330017780 | UKALL2014 |
| 330004414 | 330002149 | 0 | 110 | Curative (C) | 2013-08-01 | 2013-08-01 | Doxorubicin + Ifosfamide | N | N | 330017780 | POMB |
| 330004415 | 330002150 | 1.83 | 84 | Palliative (P) | 2015-04-19 | 2015-04-20 | Cisplatin + Etoposide + RT | 02 | null | 330017794 | PEMBROLIZUMAB |
| 330004416 | 330007186 | null | 51.9 | null | 2013-03-09 | 2013-04-02 | GC Int Guide Excranial GermCell JEB | Y | null | 330017795 | AML19 TRIAL |
| 330004417 | 330002151 | 1.85 | null | p | 2015-01-02 | 2015-01-05 | Cisplatin + Fluorouracil + RT 5day | 02 | N | 330017796 | BLEOMYCIN + CISPLATIN + VINCRISTINE |
| 330004418 | 330002152 | 1.76 | 79 | Curative (C) | 2017-07-02 | 2017-07-03 | Hydroxycarbamide | 2 | N | 330017797 | ABVD |
| 330004424 | 330002154 | 1.82 | 17.8 | Disease modification (D) | null | 2017-06-26 | Imatinib 400mg | null | null | 330017810 | BEP |
| 330004425 | 330007188 | 1.59 | 81.9 | Palliative (P) | null | 2014-03-06 | FEC 100 | N | null | 330017833 | CHOP |
| 330004426 | 330007188 | 1.85 | 82.5 | Curative (C) | 2015-05-10 | 2015-05-13 | AML17 TRIAL | 02 | null | 330017833 | FLUDARABINE |
| 330004427 | 330007188 | 1.72 | 80.5 | null | 2013-07-05 | 2013-07-05 | CETUXIMAB + CISPLATIN + FU | 2 | N | 330017833 | AML19 TRIAL |
| 330004428 | 330007188 | 1.8 | 85.4 | Curative (C) | 2016-07-25 | 2016-07-26 | CHOP R - 21 days | 2 | N | 330017833 | BORTEZOMIB |
| 330004429 | 330002155 | 1.76 | 12.3 | Disease modification (D) | 2016-08-31 | 2016-08-31 | Cisplatin + Docetaxel | null | N | 330017852 | CAPECITABINE + RT |
| 330004430 | 330002156 | 1.8 | 22.1 | Palliative (P) | 2018-09-24 | 2018-09-24 | Capecitabine + Cisplatin | N | N | 330017854 | VINBLASTINE |
| 330004431 | 330007189 | 1.73 | 90 | Curative (C) | 2017-04-17 | 2017-05-09 | Vinblastine weekly | N | N | 330017858 | AZACITIDINE |
| 330004432 | 330007189 | 1.68 | 75.5 | Disease modification (D) | 2017-05-05 | 2017-05-07 | IPILIMUMAB + NIVOLUMAB | 2 | N | 330017858 | MIFAMURTIDE |
| 330004433 | 330007189 | 1.84 | 70.7 | Palliative (P) | 2016-03-25 | 2016-04-01 | Cyclophosphamide + Topotecan | 02 | N | 330017858 | AZACITIDINE |
| 330004434 | 330002157 | 1.55 | 42 | Palliative (P) | 2015-10-01 | 2015-10-01 | Hydroxycarbamide | 02 | N | 330017878 | DHAP |
| 330004435 | 330002157 | 1.38 | 70 | Curative (C) | 2015-03-20 | 2015-04-01 | PEMBROLIZUMAB | N | N | 330017878 | ACE (GERM CELL) |
| 330004436 | 330002157 | 0 | 72.3 | Curative (C) | 2013-07-07 | 2014-01-05 | OCTREOTIDE | Y | N | 330017878 | PACLITAXEL |
| 330004437 | 330002157 | 1.66 | 88.8 | Curative (C) | 2014-12-20 | 2015-01-02 | VIDE | 02 | N | 330017878 | FCR |
| 330004438 | 330002158 | 1.65 | 53.9 | Curative (C) | 2017-01-08 | 2017-01-11 | Hydroxycarbamide | 02 | N | 330017925 | AML19 TRIAL |
| 330004442 | 330002160 | null | null | Curative (C) | 2016-08-26 | 2016-08-11 | ETOPOSIDE | null | null | 330017936 | IBRUTINIB |
| 330004443 | 330002161 | null | 74.3 | Palliative (P) | null | 2017-08-30 | Carboplatin + Pemetrexed | null | null | 330017938 | CYCLOPHOSPHAMIDE + VINCRISTINE |
| 330004444 | 330007192 | 1.75 | null | Palliative (P) | 2014-11-23 | 2014-12-13 | MITOTANE | 02 | N | 330017947 | HYDROXYCARBAMIDE |
| 330004453 | 330002164 | 1.67 | 73.6 | Palliative (P) | 2017-01-25 | 2017-01-25 | BLEOMYCIN + CISPLATIN + VINCRISTINE | Y | N | 330018010 | PEMBROLIZUMAB |
| 330004454 | 330002165 | 1.61 | 0 | Curative (C) | 2013-02-22 | 2013-02-25 | PEMBROLIZUMAB | N | N | 330018015 | PILOT TRIAL |
| 330004455 | 330002165 | 1.83 | 60.1 | Palliative (P) | 2015-08-10 | 2015-09-02 | Azacitidine | N | N | 330018015 | CAPECITABINE + CARBOPLATIN |
| 330004456 | 330002165 | 1.8 | 80 | Curative (C) | 2014-07-10 | 2014-07-14 | Cetuximab +Cisplatin + FU (Cycle 1) | 2 | N | 330018015 | IMATINIB |
| 330004458 | 330002166 | 1.63 | 58 | Curative (C) | 2014-11-16 | 2015-01-25 | CARBOPLATIN + VINCRISTINE | N | null | 330018043 | VIDE |
| 330004459 | 330002166 | null | 145.2 | Curative (C) | 2017-10-16 | 2017-11-03 | CISPLATIN + CYCLO + DOXORUBICIN | N | N | 330018043 | RUXOLITINIB |
| 330004460 | 330002166 | 0 | 56.8 | Disease modification (D) | 2015-08-07 | 2015-08-07 | AML Int Guide ADE 10+3+5 (1) | N | N | 330018043 | CYTARABINE |
| 330004461 | 330002166 | 1.63 | 91.3 | Curative (C) | 2014-03-26 | 2014-04-06 | ECX | N | Y | 330018043 | PACLITAXEL |